Chemed Co. (NYSE:CHE) saw a significant decline in short interest in May. As of May 15th, there was short interest totalling 187,800 shares, a decline of 16.5% from the April 15th total of 224,900 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily volume of 121,700 shares, the days-to-cover ratio is currently 1.5 days.
In other news, insider Kevin J. Mcnamara sold 6,000 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $331.67, for a total transaction of $1,990,020.00. Following the completion of the sale, the insider now owns 159,334 shares of the company’s stock, valued at $52,846,307.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director George J. Walsh III sold 646 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $326.83, for a total value of $211,132.18. Following the sale, the director now directly owns 7,070 shares of the company’s stock, valued at approximately $2,310,688.10. The disclosure for this sale can be found here. 3.96% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of CHE. Bbva Compass Bancshares Inc. boosted its position in shares of Chemed by 1.6% during the first quarter. Bbva Compass Bancshares Inc. now owns 2,518 shares of the company’s stock valued at $806,000 after buying an additional 39 shares during the last quarter. Hollencrest Capital Management boosted its position in shares of Chemed by 5.9% during the first quarter. Hollencrest Capital Management now owns 768 shares of the company’s stock valued at $246,000 after buying an additional 43 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Chemed by 184.8% during the first quarter. Quadrant Capital Group LLC now owns 94 shares of the company’s stock valued at $26,000 after buying an additional 61 shares during the last quarter. Bremer Trust National Association purchased a new stake in shares of Chemed during the fourth quarter valued at $25,000. Finally, Bremer Bank National Association purchased a new stake in shares of Chemed during the first quarter valued at $29,000. Hedge funds and other institutional investors own 87.47% of the company’s stock.
CHE opened at $369.35 on Thursday. The business has a fifty day moving average price of $348.47. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.70 and a current ratio of 0.73. The company has a market capitalization of $5.87 billion, a P/E ratio of 30.96, a price-to-earnings-growth ratio of 3.32 and a beta of 1.11. Chemed has a 12-month low of $260.03 and a 12-month high of $372.68.
Chemed (NYSE:CHE) last posted its quarterly earnings data on Monday, April 29th. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.96 by ($0.04). The firm had revenue of $462.03 million during the quarter, compared to the consensus estimate of $468.28 million. Chemed had a return on equity of 35.19% and a net margin of 11.37%. Chemed’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.72 EPS. On average, sell-side analysts predict that Chemed will post 12.65 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, June 19th. Stockholders of record on Thursday, May 30th were issued a dividend of $0.30 per share. The ex-dividend date of this dividend was Wednesday, May 29th. This represents a $1.20 annualized dividend and a dividend yield of 0.32%. Chemed’s payout ratio is presently 10.06%.
CHE has been the subject of a number of recent analyst reports. Oppenheimer initiated coverage on Identiv in a report on Tuesday, April 30th. They set an “outperform” rating and a $7.00 target price for the company. ValuEngine upgraded YY from a “sell” rating to a “hold” rating in a report on Friday, June 7th. Finally, Zacks Investment Research downgraded Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $347.00.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More: Understanding Analyst Recommendations
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.